Lung cancer is a leading cause of death worldwide, accounting for nearly 1.80 million deaths in 2020. It is the most common cancer in both sexes with 2.21 million new cases diagnosed in 2020. In the past few years, most Western countries have recorded a decline in lung cancer morbidity and mortality according to the American Cancer Society. This is largely due to enhanced strategies for the prevention, screening, early diagnosis, and treatment. However, lung cancer incidence is still increasing in most low- and middle-income countries, due to a lack of access to early diagnosis and treatment.
Despite improved treatment, lung cancer still has a poor prognosis and the lowest 5-year survival rate compared to other cancer sites. Multiple factors influence this, including cigarette smoking, sociodemographic factors, abnormal progression of the disease such as metastasis, and resistance to currently available anticancer therapies.
Immune checkpoint inhibitor-based immunotherapy represents one of the most significant therapeutic innovations in the oncologic landscape to date. Fortunately, an improved understanding of the tumor immune microenvironment and tumor mutanome-related neoantigen generation has revolutionized lung cancer with the promise of durable remissions in the setting of advanced disease. Initially approved for melanoma, lung cancer, and kidney cancer these therapies have now gained substantial inroads in a diversity of tumor types as first or second-line therapy and promise to extend the lives of millions of more cancer patients. Immune checkpoint blockade targeting T cell inhibitory checkpoints such as CTLA-4, programmed cell death protein 1 (PD-1), and programmed death-ligand 1 (PD-L1) have shown impressive clinical responses as monotherapy in a subset of patients. The distinctive toxicity profile associated with immune-checkpoint modulators makes them good candidates for combination strategies. However, there is critical ongoing research attempting to optimize the therapeutic utility of these agents.
This Research Topic aims to review the current state-of-the-art strategies in lung cancer therapy and provide updates on the recent advances in lung cancer immunotherapy with a focus on immune checkpoint of inhibitor biomarker development and clinical efficacy data. We welcome cutting-edge research, review articles, and correspondence from experts in the field of clinical, translational, and basic science in lung malignancies including but not limited to the following topics:
• Immune checkpoint inhibitors for lung cancer
• Immunotherapy for lung cancer
• T-cells
• PD-1 and PD-L1
• CTLA-4
• Immune-related adverse events
• Predictive biomarkers for response to immunotherapy
• Personalized treatment
• Drug resistance to immunotherapy in lung cancer
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Lung cancer is a leading cause of death worldwide, accounting for nearly 1.80 million deaths in 2020. It is the most common cancer in both sexes with 2.21 million new cases diagnosed in 2020. In the past few years, most Western countries have recorded a decline in lung cancer morbidity and mortality according to the American Cancer Society. This is largely due to enhanced strategies for the prevention, screening, early diagnosis, and treatment. However, lung cancer incidence is still increasing in most low- and middle-income countries, due to a lack of access to early diagnosis and treatment.
Despite improved treatment, lung cancer still has a poor prognosis and the lowest 5-year survival rate compared to other cancer sites. Multiple factors influence this, including cigarette smoking, sociodemographic factors, abnormal progression of the disease such as metastasis, and resistance to currently available anticancer therapies.
Immune checkpoint inhibitor-based immunotherapy represents one of the most significant therapeutic innovations in the oncologic landscape to date. Fortunately, an improved understanding of the tumor immune microenvironment and tumor mutanome-related neoantigen generation has revolutionized lung cancer with the promise of durable remissions in the setting of advanced disease. Initially approved for melanoma, lung cancer, and kidney cancer these therapies have now gained substantial inroads in a diversity of tumor types as first or second-line therapy and promise to extend the lives of millions of more cancer patients. Immune checkpoint blockade targeting T cell inhibitory checkpoints such as CTLA-4, programmed cell death protein 1 (PD-1), and programmed death-ligand 1 (PD-L1) have shown impressive clinical responses as monotherapy in a subset of patients. The distinctive toxicity profile associated with immune-checkpoint modulators makes them good candidates for combination strategies. However, there is critical ongoing research attempting to optimize the therapeutic utility of these agents.
This Research Topic aims to review the current state-of-the-art strategies in lung cancer therapy and provide updates on the recent advances in lung cancer immunotherapy with a focus on immune checkpoint of inhibitor biomarker development and clinical efficacy data. We welcome cutting-edge research, review articles, and correspondence from experts in the field of clinical, translational, and basic science in lung malignancies including but not limited to the following topics:
• Immune checkpoint inhibitors for lung cancer
• Immunotherapy for lung cancer
• T-cells
• PD-1 and PD-L1
• CTLA-4
• Immune-related adverse events
• Predictive biomarkers for response to immunotherapy
• Personalized treatment
• Drug resistance to immunotherapy in lung cancer
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
